Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases
AssigneeBaker Heart and Diabetes Institute
InventorsKarlheinz PETER, Xiaowei WANG, Jacqueline ORIAN
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating or preventing an inflammatory neurological disease in a subject, the method comprising administering to the subject a protein comprising an extracellular domain of CD39. The present invention also relates to binding proteins comprising an extracellular domain of CD39.
Claims48
A binding protein comprising an extracellular domain of CD39 and a binding region that specifically binds to activated glycoprotein (GP)IIb/IIIa.
A method of treating or preventing an inflammatory neurological disease in a subject, the method comprising administering to the subject a protein comprising an extracellular domain of CD39.
Use of a protein in the manufacture of a medicament for treating or preventing an inflammatory neurological disease in a subject, wherein the protein comprises an extracellular domain of CD39.
Use of a binding protein in the manufacture of a medicament for treating or preventing an inflammatory neurological disease in a subject, wherein the binding protein comprises:
- an extracellular domain of CD39;
- and
- a binding region that specifically binds to activated glycoprotein (GP)IIb/IIIa.
A kit for use in the treatment or prevention of an inflammatory neurological disease in a subject, the kit comprising:
- (i) at least one protein comprising an extracellular domain of CD39;
- (ii) instructions for using the kit in treating or preventing the inflammatory neurological disease in the subject;
- and
- (iii) optionally, at least one further therapeutically active compound or drug.
A kit for use in the treatment or prevention of an inflammatory neurological disease in a subject, the kit comprising:
- (i) at least one binding protein comprising
- a. an extracellular domain of CD39;
- and
- b. binding region that specifically binds to activated glycoprotein (GP)IIb/IIIa;
- (ii) instructions for using the kit in treating or preventing the inflammatory neurological disease in the subject;
- and
- (iii) optionally, at least one further therapeutically active compound or drug.
Dependencies are inferred from the claim text.